Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome - Concepedia

Concepedia

Publication | Open Access

Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome

DOI Full Paper Access

472

Citations

31

References

2012

Year

Maria Fleseriu, Beverly M. K. Biller, James W. Findling, Mark E. Molitch, D.E. Schteingart, Coleman Gross

The Journal of Clinical Endocrinology & Metabolism

Abstract

Mifepristone produced significant clinical and metabolic improvement in patients with CS with an acceptable risk-benefit profile during 6 months of treatment.

References

	Year	Citations

Page 1